4.8 Article

Red blood cell-like particles with the ability to avoid lung and spleen accumulation for the treatment of liver fibrosis

期刊

BIOMATERIALS
卷 156, 期 -, 页码 45-55

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2017.11.031

关键词

Biomimetics; Liver fibrosis; Drug delivery; Biodistribution

资金

  1. JSPS KAKENHI [26709050, 15K14146, 17H03403, 15H02296]
  2. Health Labor Sciences Research Grant from the Ministry of Health, Labour and Welfare
  3. Grants-in-Aid for Scientific Research [17H03403, 15K14146, 15H02296, 26709050] Funding Source: KAKEN

向作者/读者索取更多资源

Micro-sized drug-carrier particles accumulate mainly in the lungs and nano-sized particles tend to accumulate in the liver and spleen. Here, we show that micro-particles designed to mimic red blood cells (ABCs) can overcome these limitations. The RBC-MPs created in this study have a unique intra-particle elasticity distribution (IED), enabling them to bend around the central axis of the RBC-like dent, enabling them to pass through pores smaller than their diameter, mechanically behaving as authentic RBCs. In contrast, spherical MPs (SPH-MPs) and RBC-MPs hardened by incorporating a siloxane network (SiO2-RBC-MPs), could not. In addition to the IED, we discovered that the deformability also depends on the shape and average particle elasticity. RBC-MPs did not accumulate in the lungs and the spleen, but were targeted specifically to the liver instead. In contrast, non-RBC-MPs such as SPH-MPs and SiO2-RBC-MPs showed heavy accumulation in the lungs and/or spleen, and were dispersed non-specifically in various organs. Thus, controlling the shape and mechanical properties of RBC-MPs is important for achieving the desired biodistribution. When RBC-MPs were loaded with a (TGF)-beta receptor inhibitor, RBC-MPs could treat liver fibrosis without pneumotoxicity. (C) 2017 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据